Assessment of
kanamycin (Kn) as selective agent: The explants with a pre-cultivation time of seven days were cultured in RM supplemented with 0, 25, 50, 100, 200 and 300 mg/L of
kanamycin.
Among
kanamycin resistant isolates, 77.19% of them were aac(6')-II gene positive, but 17.14% of susceptible isolates possess this gene.
After co-cultivation, cotyledonary node explants were transferred to selective medium (MS + 2 mg L-1 6-BA + 2 mg L-1 AgNO3 + 300 mg L-1 cefotaxime + 50 mg L-1
kanamycin).
8.33% of the isolates showed resistance to a single antimicrobial (
kanamycin, tetracycline, ampicillin, and gentamycin).
was found to be maximum sensitive (Table 4) for Ciprofloxacin (83.33%) followed by Norfloxacin (83.33%), Cefotaxime (66.66%) and Ceftriaxone (50%) but less sensitive to Amikacin, Enrofloxacin, Tobramycin, Ampicillin while resistant to
Kanamycin, Amoxycillin, Cefoperazone, Cephalexin, Streptomycin and Clindamycin.
Du et al., "Label-free immunosensor for the detection of
kanamycin using Ag@[Fe.sub.3][O.sub.4] nanoparticles and thionine mixed graphene sheet," Biosensors and Bioelectronics, vol.
coli Isolates) Four Five Six Seven Eight NPS 3 1 1 0 0 (1.6%) (0.4%) (0.4%) (0.0%) (0.0%) CSO 10 7 8 9 10 (7.8%) (5.5%) (6.3%) (7.0%) (7.8%) Sample Average Source MAR Index NPS 0.07 CSO 0.36 NPS CSO NPS = nonpoint source; CSO = combined sewer overflow; MAR = multiple antibiotic resistance; Amp = ampicillin; Cam = chloramphenicol; Ctet = chlortetracyline; Kan =
kanamycin; Nal = nalidixic acid; Otet = oxytetracycline; Strp = streptomycin; Tet = tetracycline.
Extensively drug-resistant tuberculosis (XDR-TB) is defined as tuberculosis with resistance to at least isoniazid and rifampicin (MDR-TB) and further resistance to a fluoroquinolone and a second-line injectable agent (
kanamycin, amikacin, or capreomycin).
For instance, low concentrations of the synthesized nanoparticles can have stronger antibacterial effect in comparison with the common drugs such as
kanamycin.
A dramatic diagnostic innovation is a device called the KUDUwave 5000 Portable Diagnostic Audiometer, which detects impending partial or total hearing loss suffered by (among other patient groups) between 30% and 47% of people undergoing treatment for multidrug-resistant tuberculosis (MDR-TB) (about 10 000 at present).!11 The existing MDR-TB hearing loss percentages translate to about 4 000 people on the verge of mild to profound hearing loss as a result of side-effects of the toxic but lifesaving
kanamycin, a drug used in the MDRTB treatment cocktail.